The study presented robust preclinical evidence supporting the candidacy of AAVrh.74–PKP2a (RP‐A601) as a promising therapeutic intervention for PKP2‐associated ARVC, efficacious in both the incipient and advanced stages of the disease.193. Here, PKP2 is linked to arrhythmogenic right ventricular cardiomyopathy.